Scripintelligence - Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection

Science Abstracts

Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection
September 2010

Authors : David J Caldwell¹ , Jeffery D Evans²

Affliation :

¹Assistant Professor of Clinical and Administrative Sciences ULM College of Pharmacy, 1800 Bienville Drive, Monroe, LA 71201, USA ; ; dcaldwell@ulm.edu

²Assistant Professor of Clinical and Administrative Sciences ULM College of Pharmacy, 1725 Claiborne Ave., Shreveport, LA 71103, USA

DOI : 10.1517/14656560802576324

Published in : Expert Opin. Pharmacother.

Subject: Drug Evaluation

Keywords: CCR5 , chemokine coreceptor antagonist , HIV-1 infection , maraviroc , UK-427857

Abstract

Background: Maraviroc is the only...

Please Login to read the full article.

RELATED CONTENT

NEWS Scrip News

Tobira's CCR5 antagonist passes Phase IIa HIV trial
Europe to give €12 million for influenza antiviral projects
ViiV's Selzentry approved for treatment-naive HIV patients in US
HRA and Watson's emergency contraceptive ella approved in the US

Other Informa News

US FDA's 510(k) group suggests device clearance process overhaul
Prevalence of medical ghostwriting still a concern, says Senator Grassley

ANALYSIS Scrip Analysis

Executive Briefing - Getting to grips with advanced therapies in the EU
Executive Briefing - Battle lines drawn over parallel trade

Other Informa Analysis

Gene genie: the role of devices in gene therapy delivery
Industry Support of CME - the Solution, not the Problem?

COMMENT Scrip Comment

A Future for NEES

Other Informa Comment

Instilling compliance is an urgent requirement

FEATURES Scrip Features

Face-to-Face: Trophos - The French firm that hooked Actelion
Connexios: Harnessing the Indian cost advantage in network biology

Other Informa Features

Executive briefing: Remote possibilities – How rapid telehealth advances are revolutionising patient care
The annual AABB conference: balancing patient safety and cost-effectiveness